Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Catalyst Pharmaceuticals, Inc.: Strengths and Weaknesses

Highlights: Catalyst Pharmaceuticals, Inc.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Catalyst Pharmaceuticals, Inc.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

Catalyst Pharmaceuticals, Inc. SectorUnited States

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Catalyst Pharmaceuticals, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Catalyst Pharmaceuticals, Inc. SectorUnited States

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

-

Analysts' target price

-

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Catalyst Pharmaceuticals, Inc. SectorUnited States

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Catalyst Pharmaceuticals, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.85B -
BBB
- - - -
79.26B
BBB
58.62B
A
58.56B -
BBB
- -
48.75B
A
46.32B
AA
32.12B
AA
24.77B
AA
21.5B
AAA
15.97B
AA
Average 38.97B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. CPRX Stock
  4. Ratings Catalyst Pharmaceuticals, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!